CD274 and neoplasm: DNA-based next-generation sequencing (NGS) (BGI Genomics company of Shandong China, MGISEQ-2000 platform, panel of 688 genes) (Supplementary 1 Methods A1) showed no driver gene mutations with tumor mutation burden as 2.51 Muts/Mb, while PD-L1 TPS was 5% (Supplementary 2 Table A1) (Figure 1B).